a2z Radiology AI has raised a $4.5 million seed round, with participation from Khosla Ventures and SeaX Ventures, to accelerate the commercial deployment of its FDA-cleared CT triage product and to continue research and development toward broader imaging interpretation capabilities.
The Boston-based company said the financing follows two recent milestones: FDA clearance for a2z-Unified-Triage, which it described as the first system in the U.S. market able to triage seven urgent conditions on abdomen-pelvis CT scans simultaneously, and its debut at RSNA 2025, where it presented results from a prospective study evaluating AI-assisted preliminary report drafting for abdomen-pelvis CT.
According to the company, the study found that radiologists using AI assistance reduced reporting time by 17.8%, increased confidence by 14.8%, and lowered mental demand by 22.4%, while improving detection of findings without increasing false positives. a2z said the results are intended to demonstrate that comprehensive radiology AI can improve both efficiency and accuracy in real-world clinical workflows.
a2z is positioning its approach as a move beyond single-condition imaging tools, aiming to build systems that comprehensively evaluate studies in a way that aligns with how radiologists interpret complex imaging. The company cited rising imaging demand and constrained radiology capacity as a core driver, noting that abdomen-pelvis CT is the highest-volume CT category in the United States with more than 20 million exams annually.
The company said the new funding will support partnerships with health systems, continued product development, and a commercial rollout targeted for 2026.
a2z was founded in 2024 and is co-founded by Pranav Rajpurkar, PhD, an associate professor at Harvard Medical School, and Samir Rajpurkar, the company’s chief executive. The company said its long-term roadmap begins with comprehensive abdomen-pelvis analysis and expands across imaging modalities and anatomies, to make radiologist-level interpretation more accessible on demand.
KEY QUOTES:
“Radiology is one of the areas that will benefit the most from AI, ensuring no disease goes undetected,” said Vinod Khosla of Khosla Ventures. “While others focus on single conditions, a2z is able to evaluate imaging for a broad range of issues, bringing us closer to the comprehensive capabilities of a real-life radiologist.”
Vinod Khosla, Khosla Ventures
“Radiology is central to modern medicine, but delays can slow down care when timely answers are essential,” said Dr. Kid Parchariyanon, Founder and Managing Partner of SeaX Ventures. “a2z is meeting this challenge with technology that brings expert-level support directly to clinicians. We’re proud to support a2z as they build the tools that make a meaningful difference for providers and patients worldwide.”
Dr. Kid Parchariyanon, Founder and Managing Partner, SeaX Ventures
“The response at RSNA validated what we’ve been building—AI that considers everything from A to Z in each study,” said Pranav Rajpurkar, PhD, co-founder of a2z Radiology AI and Associate Professor at Harvard Medical School. “This funding lets us keep pushing on R&D while bringing our cleared technology to the care teams who need it.”
Pranav Rajpurkar, PhD, Co-Founder, a2z Radiology AI; Associate Professor, Harvard Medical School
“We’re building toward comprehensive interpretation of complex imaging studies at a level that simply hasn’t existed before,” said Samir Rajpurkar, co-founder and CEO.
Samir Rajpurkar, Co-Founder and CEO, a2z Radiology AI
